BERKELEY, CA, May  15, 2026  (GLOBE NEWSWIRE) --  Profusa, Inc. (&#34;Profusa&#34; or the &#34;Company&#34;) (NASDAQ:PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous

PFSA

Profusa Announces Listing Transfer to The Nasdaq Capital Market

Profusa Now Listed on Nasdaq Capital Market for Compliance

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>BERKELEY, CA, May  15, 2026  (GLOBE NEWSWIRE) --  Profusa, Inc. (&amp;#34;Profusa&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:PFSA), a  digital health company pioneering the next generation of technology platform enabling the continuous</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Profusa, Inc. officially transitioned to the Nasdaq Capital Market, effective May 15, 2026, marking a significant compliance milestone. This change is crucial for the company to meet bid price and stockholder equity requirements, ensuring its ongoing viability and potential growth in digital health tech.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Profusa is now listed on Nasdaq Capital Market as of May 15, 2026.</li><li>This move is part of compliance milestones set by Nasdaq Hearings Panel.</li><li>Profusa develops innovative tissue-integrated biosensors for continuous biochemistry monitoring.</li><li>It&#039;s crucial for ensuring sufficient bid price and stockholder equity compliance.</li><li>The company&#039;s technology aims to revolutionize personal health monitoring.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Profusa, Inc. (PFSA)</strong>: Listed on the Nasdaq Capital Market to facilitate compliance and enhance visibility.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement falls under Corporate Developments as it signifies a major compliance step for PFSA. Listing on a recognized exchange boosts credibility and visibility, essential for attracting investors.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Profusa&#039;s compliance with NASDAQ requirements will impact its stock stability.</li><li>The biosensor technology has potential for increased investor interest amid health tech trends.</li><li>Successful milestones could enhance market perception and stock valuations.</li><li>Increased visibility on Nasdaq could attract institutional investments.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Profusa is effective on the Nasdaq Capital Market as of May 15, 2026.</li><li>The company is based in Berkeley, California.</li><li>Profusa specializes in digital health technology and biosensors.</li><li>The compliance is part of a series of interim milestones from Nasdaq.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>PFSA is likely to see short-term volatility but could recover if compliance is secured.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">BERKELEY, CA, May  15, 2026  (GLOBE NEWSWIRE) --  Profusa, Inc. ("Profusa" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/PFSA">PFSA</a>), a  digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual's biochemistry, announces  that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market. </p>  <p align="justify">The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders' equity requirements for continued listing on the Capital Market tier.</p>  <p align="justify"><b>About Profusa</b><br></br>Based in Berkeley, CA, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.</p>  <p align="justify">"LUMEE", "PROFUSA" and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.</p>  <p>For more information, visit <a href="https://www.globenewswire.com/Tracker?data=hGzwmPWKcB2zVBRfj05B5eJlPcHS_NAnqpieWGW8DoPqmSQZ8nf3NNkP3UVej--RgvsH2doLHpgMGUh5A3rR4hrwVTpsAdKS7D628ME89xg=" rel="nofollow" target="_blank">https://profusa.com.</a></p>  <p align="justify"><b>Special Note Regarding Forward-Looking Statements</b><br></br>Certain statements in this press release may be considered "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "intend," "may," "might," "plan," "possible," "potential," "predict," "project," "propose," "seek," "should," "strive," "will," or "would" or the negatives of these terms or variations of them or similar terminology. Forward‑looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in such statements, including but not limited to the Company's ability to obtain the required stockholder approvals, execute its compliance plan within the timeframes specified by the Panel, effect and maintain compliance with the Bid Price Rule and other applicable listing requirements, complete anticipated transactions, and other factors described in the Company's filings with the Securities and Exchange Commission (the "SEC"), including its Annual Report on Form 10‑K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10‑Q and Current Reports on Form 8‑K.  The Company undertakes no obligation to update any forward‑looking statements, whether as a result of new information, future events or otherwise, except as required by law.</p>  <p><b>Contacts</b><br></br><b>Investor and Media Contacts</b><br></br>email:  <a href="https://www.globenewswire.com/Tracker?data=PwOyWzHEg_kesCzF4g5kuMj6QXhaUpXvPzN9o2fS2o9JkZHOdGDz0a_QIyNyxhApayvffgsrFZk8nySY4-TDUY4rvf3YV8MTK5DYzBQjCSg=" rel="nofollow" target="_blank">info@coreir.com</a><br></br>phone:  1 (212) 655-0924</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTcyMTA3NyM3NjA1NTI4IzUwMDA5ODI1NA=="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/YTUxNTdlMTUtYmE3NS00MGU0LWFlODEtNzM2MzRmZTc1ZjViLTUwMDA5ODI1NC0yMDI2LTA1LTE1LWVu/tiny/Profusa-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/a8137a61-b858-48da-9e47-1f1bf8f6ddba"><img src="https://ml.globenewswire.com/media/a8137a61-b858-48da-9e47-1f1bf8f6ddba/small/profusa-logo-jpg.jpg" border="0" width="150" height="53" alt="Primary Logo"></img></a></p>

Profusa, Inc. officially transitioned to the Nasdaq Capital Market, effective May 15, 2026, marking a significant compliance milestone. This change is crucial for the company to meet bid price and stockholder equity requirements, ensuring its ongoing viability and potential growth in digital health tech.

Profusa Announces Listing Transfer to The Nasdaq Capital Market

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News